Redefining the discovery and development of best-in-class oligonucleotide therapeutics
Our Mission
With OligoCreator®, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.
Global partner of choice for oligonucleotide drug discovery and development programs.
About us
We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator® platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
Mode of Action
Latest News & Events
Secarna Pharmaceuticals presents promising additional preclinical and translational data on proprietary antisense oligonucleotide SECN-15 at AACR Annual Meeting 2026
- SECN-15 constitutes promising new therapeutic option by enhancing anti-tumor immunity and overcoming resistance to checkpoint inhibitors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting
- New findings underline reprogramming mechanism in tumoral endothelial cells from angiogenic to immune-permissive, interferon-responsive state through NRP1 knockdown activity
Martinsried (Munich), Germany, April 17, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that additional preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, USA, on Monday, April 20, 2026.
Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard
- Advisory Board to provide strategic guidance as well as financial and industry expertise to support Secarna’s management team and shareholders in shaping and executing on its long-term growth trajectory
Martinsried (Munich), Germany, March 19, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the establishment of an Advisory Board to support the Company’s growth trajectory. Financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard have been appointed members of the Board.
Secarna Pharmaceuticals and Curie.Bio Expand Existing Partnership
- Expansion of existing scientific and strategic collaboration agreement announced in May 2025
- Secarna to support Curie.Bio in identifying oligonucleotide candidates for its company ventures
Martinsried (Munich), Germany, March 3, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio announced in May 2025. The expansion includes Secarna’s support in identifying oligonucleotide candidates using its proprietary OligoCreator® platform for research and development projects conducted by Curie.Bio portfolio companies.
With our AI-empowered OligoCreator® platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.
Konstantin Petropoulos, Ph.D., MBA
CEO